Skip to main content
Top
Published in: Inflammation 1/2012

01-02-2012

Antihypertensive Drugs and Inflammation in Acute Ischemic Stroke as a Predictor Factor of Future Cardiovascular Mortality

Authors: Gulcin Benbir, Birsen Ince, Emre Kumral, Zeki Ongen, Hakan Kultursay, Lale Tokgozoglu, Ali Oto, Hasan Tuzun, on the behalf of ARDA Investigators

Published in: Inflammation | Issue 1/2012

Login to get access

Abstract

The beneficial effects of antihypertensive drugs in secondary stroke prevention could not be based on their effects on lowering hypertension only.In this prospective study, the status of blood pressure, treatment regimens, new atherothrombotic event, blood sampling for hs-CRP and fibrinogen were asked at initial visit, 6th, and 12th months in 226 patients with atherothrombotic stroke.Eighty-seven percent of patients had an antihypertensive regimen, but hypertension control was achieved in 34.1% of patients.Neither use of six different antihypertensive drug regimens nor the change in blood pressure levels showed any difference on new atherothrombotic events, outcomes or survival rates.On the other hand, the higher levels of hs-CRP at baseline were found to be associated with higher mortality rates(p = 0.020).Our findings emphasize the predictive role of inflammation in future cardiovascular mortality in patients with acute ischemic stroke, indicating that inflammatory mediators underlying the atherothrombotic process play a more important role than it is assumed.
Appendix
Available only for authorised users
Literature
1.
go back to reference Preston, R.A. 2007. Effects of blood pressure reduction on cardiovascular risk estimates in hypertensive postmenopausal women. Climacteric 10: 32–41.PubMedCrossRef Preston, R.A. 2007. Effects of blood pressure reduction on cardiovascular risk estimates in hypertensive postmenopausal women. Climacteric 10: 32–41.PubMedCrossRef
2.
go back to reference Volpe, M., G. Tocci, B. Trimarco, E.A. Rosei, C. Borghi, E. Ambrosioni, A. Menotti, A. Zanchetti, and G. Mancia. 2007. Blood pressure control in Italy: Results of recent surveys on hypertension. Journal of Hypertension 25: 1491–1498.PubMedCrossRef Volpe, M., G. Tocci, B. Trimarco, E.A. Rosei, C. Borghi, E. Ambrosioni, A. Menotti, A. Zanchetti, and G. Mancia. 2007. Blood pressure control in Italy: Results of recent surveys on hypertension. Journal of Hypertension 25: 1491–1498.PubMedCrossRef
3.
go back to reference Chobanian, A.V., G.L. Bakris, H.R. Black, W.C. Cushman, L.A. Green, J.L. Izzo Jr., D.W. Jones, B.J. Materson, S. Oparil, J.T. Wright Jr., E.J. Roccella, Joint National Committee on Prevention, Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, National Heart, Lung, and Blood Institute, and National High Blood Pressure Education Program Coordinating Committee. 2003. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 42: 1206–1252.PubMedCrossRef Chobanian, A.V., G.L. Bakris, H.R. Black, W.C. Cushman, L.A. Green, J.L. Izzo Jr., D.W. Jones, B.J. Materson, S. Oparil, J.T. Wright Jr., E.J. Roccella, Joint National Committee on Prevention, Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, National Heart, Lung, and Blood Institute, and National High Blood Pressure Education Program Coordinating Committee. 2003. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 42: 1206–1252.PubMedCrossRef
4.
go back to reference Chobanian, A.V., G.L. Bakris, H.R. Black, W.C. Cushman, L.A. Green, J.L. Izzo Jr., D.W. Jones, B.J. Materson, S. Oparil, J.T. Wright Jr., E.J. Roccella, National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, and National High Blood Pressure Education Program Coordinating Committee. 2003. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 289: 2560–2572.PubMedCrossRef Chobanian, A.V., G.L. Bakris, H.R. Black, W.C. Cushman, L.A. Green, J.L. Izzo Jr., D.W. Jones, B.J. Materson, S. Oparil, J.T. Wright Jr., E.J. Roccella, National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, and National High Blood Pressure Education Program Coordinating Committee. 2003. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 289: 2560–2572.PubMedCrossRef
5.
go back to reference Neal, B., S. MacMahon, and N. Chapman. 2000. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs. Lancet 356: 1955–1964.PubMedCrossRef Neal, B., S. MacMahon, and N. Chapman. 2000. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs. Lancet 356: 1955–1964.PubMedCrossRef
6.
go back to reference PROGRESS Collaborative Group. 2001. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 358: 1033–1041.CrossRef PROGRESS Collaborative Group. 2001. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 358: 1033–1041.CrossRef
7.
go back to reference Staessen, J.A., R. Fagard, L. Thijs, H. Celis, G.G. Arabidze, W.H. Birkenhäger, C.J. Bulpitt, P.W. de Leeuw, C.T. Dollery, A.E. Fletcher, F. Forette, G. Leonetti, C. Nachev, E.T. O’Brien, J. Rosenfeld, J.L. Rodicio, J. Tuomilehto, and A. Zanchetti. 1997. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 350: 757–764.PubMedCrossRef Staessen, J.A., R. Fagard, L. Thijs, H. Celis, G.G. Arabidze, W.H. Birkenhäger, C.J. Bulpitt, P.W. de Leeuw, C.T. Dollery, A.E. Fletcher, F. Forette, G. Leonetti, C. Nachev, E.T. O’Brien, J. Rosenfeld, J.L. Rodicio, J. Tuomilehto, and A. Zanchetti. 1997. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 350: 757–764.PubMedCrossRef
8.
go back to reference Hansson, L., T. Hedner, and F.B. Dahlo. 1992. Prospective, randomized, open blinded end-point (PROBE) study. A novel design for interventional trials. Blood Pressure 1: 113–119.PubMedCrossRef Hansson, L., T. Hedner, and F.B. Dahlo. 1992. Prospective, randomized, open blinded end-point (PROBE) study. A novel design for interventional trials. Blood Pressure 1: 113–119.PubMedCrossRef
9.
go back to reference Ovbiagele, B., N.K. Hills, J.L. Saver, S.C. Johnston, and for the CASPR Investigators. 2005. Cerebrovascular event antihypertensive medications prescribed at discharge after an acute ischemic. Stroke 36: 1944–1947.PubMedCrossRef Ovbiagele, B., N.K. Hills, J.L. Saver, S.C. Johnston, and for the CASPR Investigators. 2005. Cerebrovascular event antihypertensive medications prescribed at discharge after an acute ischemic. Stroke 36: 1944–1947.PubMedCrossRef
10.
go back to reference Bonita, R., and R. Beaglehole. 1988. Modification of Rankin scale: Recovery of motor function after stroke. Stroke 19: 1497–1500.PubMedCrossRef Bonita, R., and R. Beaglehole. 1988. Modification of Rankin scale: Recovery of motor function after stroke. Stroke 19: 1497–1500.PubMedCrossRef
11.
go back to reference Wade, D.T., and C. Collin. 1988. The Barthel ADL Index: A standard measure of physical disability? International Disability Studies 10: 64–67.PubMedCrossRef Wade, D.T., and C. Collin. 1988. The Barthel ADL Index: A standard measure of physical disability? International Disability Studies 10: 64–67.PubMedCrossRef
12.
go back to reference Mahoney, F.I., and D.W. Barthel. 1965. Functional evaluation: The Barthel index. Maryland State Medical Journal 14: 61–65.PubMed Mahoney, F.I., and D.W. Barthel. 1965. Functional evaluation: The Barthel index. Maryland State Medical Journal 14: 61–65.PubMed
13.
go back to reference MOSES Study Group. 2005. Controlled study (MOSES) for secondary prevention: Principal results of a prospective randomized morbidity and mortality after stroke, eprosartan compared with nitrendipine. Stroke 36: 1218–1224.CrossRef MOSES Study Group. 2005. Controlled study (MOSES) for secondary prevention: Principal results of a prospective randomized morbidity and mortality after stroke, eprosartan compared with nitrendipine. Stroke 36: 1218–1224.CrossRef
14.
go back to reference Di Napoli, M., M. Schwaninger, R. Cappelli, E. Ceccarelli, G. Di Gianfilippo, C. Donati, H.C.A. Emsley, S. Forconi, S.J. Hopkins, L. Masotti, K.W. Muir, A. Paciucci, F. Papa, S. Roncacci, D. Sander, K. Sander, C.J. Smith, A. Stefanini, and D. Weber. 2005. Evaluation of C-Reactive protein measurement for assessing the risk and prognosis in ischemic stroke. A statement for health care professionals from the CRP pooling. Stroke 36: 1316–29.PubMedCrossRef Di Napoli, M., M. Schwaninger, R. Cappelli, E. Ceccarelli, G. Di Gianfilippo, C. Donati, H.C.A. Emsley, S. Forconi, S.J. Hopkins, L. Masotti, K.W. Muir, A. Paciucci, F. Papa, S. Roncacci, D. Sander, K. Sander, C.J. Smith, A. Stefanini, and D. Weber. 2005. Evaluation of C-Reactive protein measurement for assessing the risk and prognosis in ischemic stroke. A statement for health care professionals from the CRP pooling. Stroke 36: 1316–29.PubMedCrossRef
15.
go back to reference Sung, K.C., J.Y. Sh, B.S. Kim, J.H. Kang, H. Kim, M.H. Lee, J.R. Park, and S.W. Kim. 2003. High sensitivity C-reactive protein as an independent risk factor for essential hypertension. American Journal of Hypertension 16: 429–433.PubMedCrossRef Sung, K.C., J.Y. Sh, B.S. Kim, J.H. Kang, H. Kim, M.H. Lee, J.R. Park, and S.W. Kim. 2003. High sensitivity C-reactive protein as an independent risk factor for essential hypertension. American Journal of Hypertension 16: 429–433.PubMedCrossRef
16.
go back to reference Bautista, L.E., P. Lopez-Jaramillo, L.M. Vera, J.P. Casas, A.P. Otero, and A.I. Guaracao. 2001. Is C-reactive protein an independent risk factor for essential hypertension? Journal of Hypertension 19: 857–861.PubMedCrossRef Bautista, L.E., P. Lopez-Jaramillo, L.M. Vera, J.P. Casas, A.P. Otero, and A.I. Guaracao. 2001. Is C-reactive protein an independent risk factor for essential hypertension? Journal of Hypertension 19: 857–861.PubMedCrossRef
17.
go back to reference Benbir, G., M. Bozluolcay, and B. Ince. 2005. Is the level of C-reactive protein correlated with the extent of carotid atherosclerosis? Acta Neurologica Belgica 105: 73–80.PubMed Benbir, G., M. Bozluolcay, and B. Ince. 2005. Is the level of C-reactive protein correlated with the extent of carotid atherosclerosis? Acta Neurologica Belgica 105: 73–80.PubMed
18.
go back to reference Dahlof, B., R.B. Devereux, S.E. Kjeldsen, S. Julius, G. Beevers, U. de Faire, F. Fyhrquist, H. Ibsen, K. Kristiansson, O. Lederballe-Pedersen, L.H. Lindholm, M.S. Nieminen, P. Omvik, S. Oparil, H. Wedel, and LIFE Study Group. 2002. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 359: 995–1003.PubMedCrossRef Dahlof, B., R.B. Devereux, S.E. Kjeldsen, S. Julius, G. Beevers, U. de Faire, F. Fyhrquist, H. Ibsen, K. Kristiansson, O. Lederballe-Pedersen, L.H. Lindholm, M.S. Nieminen, P. Omvik, S. Oparil, H. Wedel, and LIFE Study Group. 2002. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 359: 995–1003.PubMedCrossRef
19.
go back to reference Schrader, J., M. Rothemeyer, S. Luders, and K. Kollmann. 1998. Hypertension and stroke–rationale behind the ACCESS trial. Acute candesartan cilexetil evaluation in stroke survivors. Basic Research in Cardiology 93: 69–78.PubMedCrossRef Schrader, J., M. Rothemeyer, S. Luders, and K. Kollmann. 1998. Hypertension and stroke–rationale behind the ACCESS trial. Acute candesartan cilexetil evaluation in stroke survivors. Basic Research in Cardiology 93: 69–78.PubMedCrossRef
20.
go back to reference Schrader, J., S. Lüders, A. Kulschewski, J. Berger, W. Zidek, J. Treib, K. Einhäupl, H.C. Diener, P. Dominiak, and Acute candesartan cilexetil therapy in stroke survivors study group. 2003. The ACCESS study: Evaluation of acute candesartan cilexetil therapy in stroke survivors. Stroke 34: 1699–1703.PubMedCrossRef Schrader, J., S. Lüders, A. Kulschewski, J. Berger, W. Zidek, J. Treib, K. Einhäupl, H.C. Diener, P. Dominiak, and Acute candesartan cilexetil therapy in stroke survivors study group. 2003. The ACCESS study: Evaluation of acute candesartan cilexetil therapy in stroke survivors. Stroke 34: 1699–1703.PubMedCrossRef
21.
go back to reference PATS Collaborating Group. 1995. Post-stroke antihypertensive treatment study. A preliminary result. Chinese Medical Journal 108: 710–717. PATS Collaborating Group. 1995. Post-stroke antihypertensive treatment study. A preliminary result. Chinese Medical Journal 108: 710–717.
22.
go back to reference Thone-Reineke, C., U.M. Steckelings, and T. Unger. 2006. Angiotensin receptor blockers and cerebral protection in stroke. Journal of Hypertension. Supplement 24: 115–121.CrossRef Thone-Reineke, C., U.M. Steckelings, and T. Unger. 2006. Angiotensin receptor blockers and cerebral protection in stroke. Journal of Hypertension. Supplement 24: 115–121.CrossRef
23.
go back to reference Heart Outcome Prevention Evaluation Study Investigators. 2000. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The New England Journal of Medicine 342: 145–153.CrossRef Heart Outcome Prevention Evaluation Study Investigators. 2000. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The New England Journal of Medicine 342: 145–153.CrossRef
24.
go back to reference Qureshi, A., M.F. Suri, L.R. Guterman, and L.N. Hopkins. 2001. Ineffective secondary prevention in survivors of cardiovascular events in the US population: Report from the third national health and nutrition examination survey. Archives of Internal Medicine 161: 1621–1628.PubMedCrossRef Qureshi, A., M.F. Suri, L.R. Guterman, and L.N. Hopkins. 2001. Ineffective secondary prevention in survivors of cardiovascular events in the US population: Report from the third national health and nutrition examination survey. Archives of Internal Medicine 161: 1621–1628.PubMedCrossRef
25.
go back to reference Hillen, T., R. Dundas, E. Lawrence, J.A. Stewart, A.G. Rudd, and C.D. Wolfe. 2000. Antithrombotic and antihypertensive management 3 months after ischemic stroke: A prospective study in an inner city population. Stroke 31: 469–475.PubMedCrossRef Hillen, T., R. Dundas, E. Lawrence, J.A. Stewart, A.G. Rudd, and C.D. Wolfe. 2000. Antithrombotic and antihypertensive management 3 months after ischemic stroke: A prospective study in an inner city population. Stroke 31: 469–475.PubMedCrossRef
26.
go back to reference Law, M., N.J. Wald, J.K. Morris, and R.E. Jordan. 2003. Value of low-dose combination treatment with blood pressure lowering drugs: Analysis of 354 randomised trials. BMJ 326: 1427.PubMedCrossRef Law, M., N.J. Wald, J.K. Morris, and R.E. Jordan. 2003. Value of low-dose combination treatment with blood pressure lowering drugs: Analysis of 354 randomised trials. BMJ 326: 1427.PubMedCrossRef
27.
go back to reference Khan, N., F.A. McAlister, N.R. Campbell, R.D. Feldman, S. Rabkin, J. Mahon, R. Lewanczuk, K.B. Zarnke, B. Hemmelgarn, M. Lebel, M. Levine, C. Herbert, and Canadian Hypertension Education Program. 2004. The 2004 Canadian recommendations for the management of hypertension: Part II-therapy. The Canadian Journal of Cardiology 20: 41–54.PubMed Khan, N., F.A. McAlister, N.R. Campbell, R.D. Feldman, S. Rabkin, J. Mahon, R. Lewanczuk, K.B. Zarnke, B. Hemmelgarn, M. Lebel, M. Levine, C. Herbert, and Canadian Hypertension Education Program. 2004. The 2004 Canadian recommendations for the management of hypertension: Part II-therapy. The Canadian Journal of Cardiology 20: 41–54.PubMed
28.
go back to reference Cao, J.J., C. Thach, T.A. Manolio, B.M. Psaty, L.H. Kuller, P.H. Chaves, J.F. Polak, K. Sutton-Tyrrell, D.M. Herrington, T.R. Price, and M. Cushman. 2003. C-reactive protein, carotid intima-media thickness, and incidence of ischemic stroke in the elderly: The cardiovascular health study. Circulation 108: 166–170.PubMedCrossRef Cao, J.J., C. Thach, T.A. Manolio, B.M. Psaty, L.H. Kuller, P.H. Chaves, J.F. Polak, K. Sutton-Tyrrell, D.M. Herrington, T.R. Price, and M. Cushman. 2003. C-reactive protein, carotid intima-media thickness, and incidence of ischemic stroke in the elderly: The cardiovascular health study. Circulation 108: 166–170.PubMedCrossRef
29.
go back to reference Hashimoto, H., K. Kitagawa, H. Hougaku, H. Etani, and M. Hori. 2004. Relationship between C-reactive protein and progression of early carotid atherosclerosis in hypertensive subjects. Stroke 35: 1625–1630.PubMedCrossRef Hashimoto, H., K. Kitagawa, H. Hougaku, H. Etani, and M. Hori. 2004. Relationship between C-reactive protein and progression of early carotid atherosclerosis in hypertensive subjects. Stroke 35: 1625–1630.PubMedCrossRef
30.
go back to reference Muir, K.W., C.J. Weir, W. Alwan, I.B. Squire, and K.R. Lees. 1999. C-reactive protein and outcome after ischemic stroke. Stroke 30: 981–985.PubMedCrossRef Muir, K.W., C.J. Weir, W. Alwan, I.B. Squire, and K.R. Lees. 1999. C-reactive protein and outcome after ischemic stroke. Stroke 30: 981–985.PubMedCrossRef
31.
go back to reference Di Napoli, M., and F. Papa. 2003. Association between blood pressure and c-reactive protein levels in acute ischemic stroke. Hypertension 42: 1117–1123.PubMedCrossRef Di Napoli, M., and F. Papa. 2003. Association between blood pressure and c-reactive protein levels in acute ischemic stroke. Hypertension 42: 1117–1123.PubMedCrossRef
32.
go back to reference Fulop, T., A.D. Rule, D.W. Schmidt, H.J. Wiste, K.R. Bailey, I.J. Kullo, G.L. Schwartz, T.H. Mosley, E. Boerwinkle, and S.T. Turner. 2009. C-reactive protein among community-dwelling hypertensives on single-agent antihypertensive treatment. J Am Soc Hypertens 3: 260–266.PubMedCrossRef Fulop, T., A.D. Rule, D.W. Schmidt, H.J. Wiste, K.R. Bailey, I.J. Kullo, G.L. Schwartz, T.H. Mosley, E. Boerwinkle, and S.T. Turner. 2009. C-reactive protein among community-dwelling hypertensives on single-agent antihypertensive treatment. J Am Soc Hypertens 3: 260–266.PubMedCrossRef
33.
go back to reference Palmas, W., S. Ma, B. Psaty, D.C. Goff, C. Darwin, and R.G. Barr. 2007. Antihypertensive medications and C-reactive protein in the muli-ethnic study of atherosclerosis. American Journal of Hypertension 20: 233–241.PubMedCrossRef Palmas, W., S. Ma, B. Psaty, D.C. Goff, C. Darwin, and R.G. Barr. 2007. Antihypertensive medications and C-reactive protein in the muli-ethnic study of atherosclerosis. American Journal of Hypertension 20: 233–241.PubMedCrossRef
Metadata
Title
Antihypertensive Drugs and Inflammation in Acute Ischemic Stroke as a Predictor Factor of Future Cardiovascular Mortality
Authors
Gulcin Benbir
Birsen Ince
Emre Kumral
Zeki Ongen
Hakan Kultursay
Lale Tokgozoglu
Ali Oto
Hasan Tuzun
on the behalf of ARDA Investigators
Publication date
01-02-2012
Publisher
Springer US
Published in
Inflammation / Issue 1/2012
Print ISSN: 0360-3997
Electronic ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-010-9290-4

Other articles of this Issue 1/2012

Inflammation 1/2012 Go to the issue